{"id":"https://openalex.org/W3133516735","doi":"https://doi.org/10.1200/jco.2021.39.6_suppl.287","title":"The impact of hypertension on response rates in patients with renal cell carcinoma.","display_name":"The impact of hypertension on response rates in patients with renal cell carcinoma.","publication_year":2021,"publication_date":"2021-02-20","ids":{"openalex":"https://openalex.org/W3133516735","doi":"https://doi.org/10.1200/jco.2021.39.6_suppl.287","mag":"3133516735"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2021.39.6_suppl.287","doi":"https://doi.org/10.1200/jco.2021.39.6_suppl.287","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.6_suppl.287","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069826071","display_name":"Diana Vesselinovitch Maslov","orcid":"https://orcid.org/0000-0002-3640-3042","observed_orcids":["https://orcid.org/0000-0002-3640-3042"]},"institutions":[{"id":"https://openalex.org/I1336053918","display_name":"Ochsner Health System","ror":"https://ror.org/003ngne20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diana Maslov","raw_affiliation_strings":["Ochsner Health System, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ochsner Health System, New Orleans, LA;","institution_ids":["https://openalex.org/I1336053918"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081778292","display_name":"Karine Tawagi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1336053918","display_name":"Ochsner Health System","ror":"https://ror.org/003ngne20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karine Tawagi","raw_affiliation_strings":["Ochsner Health System, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ochsner Health System, New Orleans, LA;","institution_ids":["https://openalex.org/I1336053918"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084362236","display_name":"Madhav KC","orcid":"https://orcid.org/0000-0002-4659-4348","observed_orcids":["https://orcid.org/0000-0002-4659-4348","https://orcid.org/0000-0002-2477-2721"]},"institutions":[{"id":"https://openalex.org/I75420490","display_name":"Louisiana State University Health Sciences Center New Orleans","ror":"https://ror.org/01qv8fp92","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121820613","https://openalex.org/I75420490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Madhav KC","raw_affiliation_strings":["LSU Health Sciences Center School of Public Health, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LSU Health Sciences Center School of Public Health, New Orleans, LA;","institution_ids":["https://openalex.org/I75420490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004438656","display_name":"Richa Goel","orcid":"https://orcid.org/0000-0002-5919-3084","observed_orcids":["https://orcid.org/0000-0002-5919-3084"]},"institutions":[{"id":"https://openalex.org/I1336053918","display_name":"Ochsner Health System","ror":"https://ror.org/003ngne20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richa Goel","raw_affiliation_strings":["Ochsner Health System, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ochsner Health System, New Orleans, LA;","institution_ids":["https://openalex.org/I1336053918"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110588213","display_name":"Helen Yuan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1336053918","display_name":"Ochsner Health System","ror":"https://ror.org/003ngne20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Helen Yuan","raw_affiliation_strings":["Ochsner Health System, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ochsner Health System, New Orleans, LA;","institution_ids":["https://openalex.org/I1336053918"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032864947","display_name":"Adi Bamnolker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1336053918","display_name":"Ochsner Health System","ror":"https://ror.org/003ngne20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adi Bamnolker","raw_affiliation_strings":["Ochsner Health System, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ochsner Health System, New Orleans, LA;","institution_ids":["https://openalex.org/I1336053918"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068400172","display_name":"Zo\u00eb Blake","orcid":"https://orcid.org/0000-0002-3924-8690","observed_orcids":["https://orcid.org/0000-0002-3924-8690"]},"institutions":[{"id":"https://openalex.org/I165143802","display_name":"The University of Queensland","ror":"https://ror.org/00rqy9422","country_code":"AU","type":"education","lineage":["https://openalex.org/I165143802"]},{"id":"https://openalex.org/I2799767083","display_name":"Ochsner Medical Center","ror":"https://ror.org/0290qyp66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918","https://openalex.org/I2799767083"]}],"countries":["AU","US"],"is_corresponding":false,"raw_author_name":"Zoe Blake","raw_affiliation_strings":["University of Queensland Ochsner Clinical School, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Queensland Ochsner Clinical School, New Orleans, LA;","institution_ids":["https://openalex.org/I165143802","https://openalex.org/I2799767083"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073976392","display_name":"William Y. Song","orcid":"https://orcid.org/0009-0003-3196-2368","observed_orcids":["https://orcid.org/0009-0003-3196-2368"]},"institutions":[{"id":"https://openalex.org/I165143802","display_name":"The University of Queensland","ror":"https://ror.org/00rqy9422","country_code":"AU","type":"education","lineage":["https://openalex.org/I165143802"]},{"id":"https://openalex.org/I2799767083","display_name":"Ochsner Medical Center","ror":"https://ror.org/0290qyp66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918","https://openalex.org/I2799767083"]}],"countries":["AU","US"],"is_corresponding":false,"raw_author_name":"William Song","raw_affiliation_strings":["University of Queensland Ochsner Clinical School, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Queensland Ochsner Clinical School, New Orleans, LA;","institution_ids":["https://openalex.org/I165143802","https://openalex.org/I2799767083"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101799590","display_name":"Daniel Hartman Johnson","orcid":"https://orcid.org/0000-0002-4778-686X","observed_orcids":["https://orcid.org/0000-0002-4778-686X"]},"institutions":[{"id":"https://openalex.org/I1336053918","display_name":"Ochsner Health System","ror":"https://ror.org/003ngne20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Johnson","raw_affiliation_strings":["Ochsner Health System, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ochsner Health System, New Orleans, LA;","institution_ids":["https://openalex.org/I1336053918"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051542399","display_name":"Marc Ryan Matrana","orcid":"https://orcid.org/0000-0002-7301-170X","observed_orcids":["https://orcid.org/0000-0002-7301-170X"]},"institutions":[{"id":"https://openalex.org/I2799767083","display_name":"Ochsner Medical Center","ror":"https://ror.org/0290qyp66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918","https://openalex.org/I2799767083"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marc Ryan Matrana","raw_affiliation_strings":["Ochsner Cancer Institute, New Orleans, LA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ochsner Cancer Institute, New Orleans, LA;","institution_ids":["https://openalex.org/I2799767083"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"39","issue":"6_suppl","first_page":"287","last_page":"287"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.7760000228881836},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.8949999809265137},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.8289999961853027},{"id":"https://openalex.org/keywords/uncontrolled-hypertension","display_name":"uncontrolled hypertension","score":0.6620000004768372},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.6840000152587891},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.890999972820282},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/pazopanib","display_name":"pazopanib","score":0.8109999895095825},{"id":"https://openalex.org/keywords/sunitinib","display_name":"sunitinib","score":0.9670000076293945},{"id":"https://openalex.org/keywords/cabozantinib","display_name":"cabozantinib","score":0.9900000095367432},{"id":"https://openalex.org/keywords/axitinib","display_name":"axitinib","score":0.5799999833106995},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.5360000133514404},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8489999771118164},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9369999766349792},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.6899999976158142}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9665599465370178},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.8029656410217285},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7281040549278259},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.7236015796661377},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6641585826873779},{"id":"https://openalex.org/C2776539811","wikidata":"https://www.wikidata.org/wiki/Q4830631","display_name":"Axitinib","level":4,"score":0.6571412086486816},{"id":"https://openalex.org/C2778439243","wikidata":"https://www.wikidata.org/wiki/Q7157043","display_name":"Pazopanib","level":4,"score":0.6172231435775757},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6073384284973145},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.5930210947990417},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.4688471555709839},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.42942726612091064},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41711336374282837},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3853938579559326},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.31248801946640015},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.23868969082832336}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2021.39.6_suppl.287","doi":"https://doi.org/10.1200/jco.2021.39.6_suppl.287","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2021.39.6_suppl.287","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3047817277","https://openalex.org/W2521596142","https://openalex.org/W2044425343","https://openalex.org/W2602114905","https://openalex.org/W2953716919","https://openalex.org/W2601481333","https://openalex.org/W4400271991","https://openalex.org/W2036515537","https://openalex.org/W2562694235","https://openalex.org/W7154448760"],"abstract_inverted_index":{"287":[0],"Background:":[1],"There":[2,267],"are":[3,354],"many":[4,31,305],"clinical":[5,111,327],"trials":[6],"that":[7],"demonstrate":[8],"the":[9],"benefits":[10],"of":[11,26,56,110,121,142,149,176,194,204,210,216,230,280,287,309,318,342],"immunotherapies":[12],"and":[13,42,48,108,128,183],"targeted":[14,90],"therapies":[15],"in":[16,51,74,272,294,334,337,360],"patients":[17,52,150,195,212,263,306,325,361],"(pts)":[18],"with":[19,34,53,84,87,245,253,277,284,339,347,362],"advanced":[20],"or":[21,125,293],"metastatic":[22],"RCC":[23,71,131],"(mRCC).":[24],"Most":[25],"these":[27],"studies":[28,66,353],"specifically":[29],"exclude":[30],"real-world":[32,75],"pts":[33,83,144],"comorbidities":[35],"such":[36,115],"as":[37,61,116],"autoimmune":[38,122],"disease,":[39,123],"heart":[40,118],"failure,":[41,119,127],"hypertension.":[43,218],"Data":[44,302],"on":[45,174,222,303,311,364],"treatment":[46,96,100,102,224],"efficacy":[47],"adverse":[49],"events":[50],"a":[54,202,278,340],"history":[55,203,215,229,279,286,341],"uncontrolled":[57,205,217,288],"hypertension":[58,231,246,255,281,289,310,322,343,363],"is":[59],"lacking,":[60],"there":[62],"have":[63],"been":[64],"few":[65],"analyzing":[67],"more":[68],"recently":[69],"approved":[70],"drug":[72],"regimens":[73],"practice.":[76],"Methods:":[77],"We":[78,330],"retrospectively":[79],"collected":[80],"data":[81],"from":[82,326],"mRCC":[85],"treated":[86],"immunotherapy":[88],"and/or":[89],"therapies.":[91],"Patient":[92],"characteristics,":[93],"performance":[94],"status,":[95],"type,":[97],"reason":[98],"for":[99,198,243,251,261,367],"discontinuation,":[101],"response/progression":[103],"per":[104],"RECIST":[105],"v1.1,":[106],"survival,":[107],"presence":[109,120],"trial":[112,328],"exclusion":[113],"criteria":[114],"hypertension,":[117,206],"renal":[124],"liver":[126],"International":[129],"Metastatic":[130],"Database":[132],"Consortium":[133],"(IMDC)":[134],"Risk":[135],"score":[136],"were":[137,145,173],"collected.":[138],"Results:":[139],"A":[140,228],"total":[141,211],"198":[143],"included.":[146],"The":[147,219],"majority":[148],"received":[151,185],"Tyrosine":[152],"Kinase":[153],"Inhibitors":[154],"(TKIs)":[155],"(42.42%":[156],"pazopanib":[157],"(n":[158,163,168,180,189],"=":[159,164,169,181,190,257,291,300],"84),":[160],"21.71%":[161],"sunitinib":[162],"43),":[165],"13.64%":[166],"cabozantinib":[167],"27)),":[170],"whereas":[171,207],"10.61%":[172],"combination":[175],"axitinib":[177],"+":[178,187],"pembrolizumab":[179],"21)":[182],"11.62%":[184],"ipilimumab":[186],"nivolumab":[188],"23),":[191],"and.":[192],"71.72%":[193],"who":[196],"qualified":[197],"systemic":[199,365],"therapy":[200,312,366],"had":[201,213],"28.28":[208],"%":[209],"no":[214,254,270,285,332],"median":[220,241,249,335],"time":[221,317],"first-line":[223],"was":[225,264,268],"5.17":[226],"months.":[227,266],"did":[232],"not":[233],"significantly":[234],"affect":[235],"Overall":[236],"Survival":[237,297],"(OS),":[238],"15.90":[239],"months":[240],"OS":[242,250,260,336],"those":[244,252,276,283,338,346],"vs":[247,282],"27.80":[248],"(p":[256,290,299],"0.38).":[258],"Median":[259],"all":[262],"22.80":[265],"also":[269],"difference":[271,333],"response":[273],"rate":[274],"between":[275],"0.65)":[292],"Progression":[295],"Free":[296],"(PFS)":[298],"0.97)":[301],"how":[304],"developed":[307],"exacerbations":[308],"will":[313],"be":[314],"available":[315],"at":[316],"presentation.":[319],"Conclusions:":[320],"Uncontrolled":[321],"typically":[323],"excludes":[324],"enrollment.":[329],"found":[331],"compared":[344],"to":[345,356],"normal":[348],"blood":[349],"pressures.":[350],"Further":[351],"large-scale":[352],"needed":[355],"further":[357],"determine":[358],"outcomes":[359],"mRCC.":[368]},"counts_by_year":[],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2021-03-15T00:00:00"}